This $197,748 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is funding research to enhance low-dose buprenorphine initiation protocols for individuals with opioid use disorder who are using fentanyl. The primary objectives are to: 1) identify barriers to successful completion of low-dose buprenorphine initiation, 2) design an enhanced low-dose initiation program using input from patients,...
This Project Grant award of $235,542 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the safety of using extended-release buprenorphine (XR-BUP) as a low-dose induction strategy for opioid use disorder (OUD) treatment. The primary aim is to determine the safety of administering different doses of XR-BUP (16mg, 24mg, 32mg) without first requiring patients to experience opioid withdrawal symptoms or use...
This $4,920,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a randomized controlled trial to investigate the feasibility, acceptability, and preliminary effectiveness of using long-acting injectable naltrexone as a preventive measure for opioid overdose in individuals using stimulants and living with or at risk of HIV. The key objectives are to: 1) assess the use of naltrexone for...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neuropeptide S receptor 1 (NPSR1) as a potential target for reducing opioid self-administration and relapse in opioid use disorder. The research aims to evaluate whether NPSR1 agonism can alleviate the anxious phenotype observed during opioid withdrawal, which contributes to the intensified motivation to seek...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop efficient statistical methods for data fusion to improve the power and external validity of clinical trials for treating opioid use disorder. The $564,326 award, with a performance period from August 2024 to May 2029, will fund the development of new parametric and semiparametric estimators for average treatment effects,...
The National Institute on Drug Abuse (NIDA) awarded a $19,302,777 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a novel medication for the treatment of opioid use disorder (OUD). The project aims to advance late-stage chemistry, manufacturing, and controls (CMC), conduct registration-enabling non-clinical studies, establish quality systems, and engage with the FDA to expedite NRS-033 into...
This Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports preclinical research to investigate the potential of targeting the neuropeptide S (NPS) receptor as a treatment for opioid use disorder. The $419,876 award, with a performance period from September 2024 to August 2026, aims to conduct proof-of-concept studies to determine whether NPS receptor-targeted molecules can reduce oxycodone taking...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Federal Grant Program "Drug Use and Addiction Research Programs" (CFDA 93.279), will fund research to simulate the potential impacts of different methadone treatment policy scenarios in New York State. The $683,583 award, spanning 2 years from August 1, 2024 to July 31, 2026, will support the development of an agent-based computer simulation model to estimate the effects of policy changes such as...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of novel econometric research methods to integrate real-world data and evidence (RWE) into inconclusive randomized controlled trials (RCTs) for opioid use disorder (OUD) treatments. The $2,542,500 award to Weill Medical College of Cornell University will fund a 3-year project to adapt existing econometric and...
This federal Project Grant award of $1,264,863 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a study to evaluate the efficacy of combined guanfacine (GXR) and mindfulness-based recovery enhancement (MORE) as an adjunct to buprenorphine maintenance treatment for individuals with opioid use disorder (OUD). The study will first confirm the independent and combined efficacy of GXR and MORE in a sample of 80 OUD...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), will support a randomized controlled trial examining the use of extended-release injectable buprenorphine in adults with opioid use disorder (OUD) who use high-potency synthetic opioids (HPSO). The $360,720 award, granted to The Trustees of Columbia University in the City of New York, will be used to compare abstinence and relapse rates between those receiving the injectable buprenorphine formulation versus sublingual buprenorphine/naloxone. The study will also explore the relationship between HPSO levels, withdrawal symptoms, and treatment outcomes. This research aims to optimize medication-based OUD treatment in the context of the proliferation of highly potent synthetic opioids and enhance understanding of individual factors influencing treatment response. The award period runs from August 15, 2024 to July 31, 2029.